Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - cefepime dihydrochloride monohydrate 1,213 g - eq. cefepime 1000 mg - powder for solution for injection/infusion - 1 g - cefepime dihydrochloride monohydrate 1213 mg - cefepime

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - cefepime dihydrochloride monohydrate 2,426 g - eq. cefepime 2000 mg - powder for solution for injection/infusion - 2 g - cefepime dihydrochloride monohydrate 2426 g - cefepime

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cefepime dihydrochloride monohydrate 1,19 g - eq. cefepime 1 g - powder for solution for injection/infusion - 1 g - cefepime dihydrochloride monohydrate 1.19 g - cefepime

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cefepime dihydrochloride monohydrate 2,38 g - eq. cefepime 2 g - powder for solution for injection/infusion - 2 g - cefepime dihydrochloride monohydrate 2.38 g - cefepime

Stati Uniti - inglese - NLM (National Library of Medicine)

sandoz inc - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection, usp is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also precautions: pediatric use and dosage and administration ): pneumonia (moderate to severe) caused by streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. empiric therapy for febrile neutropenic patients. cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (see clinical studies .) uncomplicated and complicated urinary tract infection

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - cefepime dihydrochloride monohydrate 1.1892 g equivalent to cefepime 1g - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.1892 g equivalent to cefepime 1g excipient: arginine - adults: cefepime kabi is indicated for the treatment of the indications listed below when caused by susceptible bacteria: · lower respiratory tract infections, including pneumonia and bronchitis · urinary tract infections , both complicated, including pyelonephritis, and uncomplicated infections · skin and skin structure infections · intra-abdominal infections, including peritonitis and biliary tract infections · septicaemia · empiric treatment in febrile neutropenic patients.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - cefepime dihydrochloride monohydrate 2.3785 g equivalent to cefepime 2g - powder for injection - 2 g - active: cefepime dihydrochloride monohydrate 2.3785 g equivalent to cefepime 2g excipient: arginine - adults: cefepime kabi is indicated for the treatment of the indications listed below when caused by susceptible bacteria: · lower respiratory tract infections, including pneumonia and bronchitis · urinary tract infections , both complicated, including pyelonephritis, and uncomplicated infections · skin and skin structure infections · intra-abdominal infections, including peritonitis and biliary tract infections · septicaemia · empiric treatment in febrile neutropenic patients.

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

noridem enterprises ltd. - cefepime dihydrochloride monohydrate 1189 mg - eq. cefepime 1000 mg - powder for solution for injection/infusion - 1 g - cefepime dihydrochloride monohydrate 1189 mg - cefepime

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

noridem enterprises ltd. - cefepime dihydrochloride monohydrate 2378 mg - eq. cefepime 2000 mg - powder for solution for injection/infusion - 2 g - cefepime dihydrochloride monohydrate 2378 mg - cefepime

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

viatris limited - cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base; cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base excipient: arginine active: cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.